← All trials
NCT05508477
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2022
- Primary completion
- Mar 28, 2023
- Completion date
- May 28, 2023
- First posted
- Aug 19, 2022
- Last posted
- Aug 29, 2022
- Enrollment
- 4005
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dr. Soetomo General HospitalLead sponsor
- Government of IndonesiaCollaborator
- Airlangga UniversityCollaborator
- Dr. Soetomo General HospitalOverall official - principal investigator
- Biotis Pharmaceuticals, IndonesiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.